On July 9, WuXi Biologics rose 3.03% in regular trading, trading at HK$37.32/share, with turnover of HK$269 million.

On the news front, the Life Sciences Tools & Services sector staged a collective rebound after two consecutive sessions of weakness. INSILICO gained 6.97%, WuXi XDC rose 4.29%, XtalPi climbed 3.64%, Pharmaron advanced 2.97%, and WuXi AppTec added 2.87%, reflecting significant sector resonance.

The company maintained its high-frequency buyback rhythm, repurchasing approximately 2.7165 million shares on July 7 for about HK$99.82 million, bringing the cumulative buyback amount to HK$1.272 billion year-to-date. This sustained capital deployment signals management confidence in the company's intrinsic value.

Additionally, UBS previously raised its target price for WuXi Biologics to HK$51.1, maintaining a Buy rating, citing strong order momentum, favorable pricing trends with new contract prices up 5%-15%, and reaffirmed revenue guidance of 13%-17% year-over-year growth. The current share price implies approximately 27% upside to the UBS target.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)